Pudafensine is advancing in late-stage clinical trials for both erectile dysfunction and vulvodynia, targeting large unmet needs with a unique dual mechanism and strong safety profile. Partnering discussions are intensifying, with key data readouts expected by year-end 2024.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.